BIOGEN INC.
NASDAQ: BIIB
▲
278.03
+2.90
+1.05%
1 Day
-
Open
275.44
-
Previous Close
275.13
-
Volume (Avg)
1.20M (862.91k)
-
Day's Range
275.44-279.00
-
52Wk Range
187.16-311.88
-
Market Cap.
40.17B
-
Dividend Rate ( Yield)
-
-
Beta
-
-
Shares Outstanding
-
-
P/E Ratio (EPS)
13.15 (-)
Top Stories
-
Alzheimer’s Breakthrough? Researchers Find New Omega-3 Acid That Could Reduce Vision Loss In Patients
Forbes 4 days ago -
Alzheimer’s Blood Test That Could Help Diagnose Disease Earlier Is Being Developed By Eli Lilly And Roche
Forbes -
Former head of research at J&J to run Cambridge biotech FogPharma
The Boston Globe -
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
Benzinga -
VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver Best Returns?
TipRanks 4 days ago -
Clinic, CWRU among Ohio sites participating in study to slow brain changes leading to Alzheimer’s
The Plain Dealer Cleveland -
FDA advisers give partial backing to ALS drug
Axios -
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Zacks.com -
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
Zacks.com -
AbbVie (ABBV) Provides Clinical Updates on Inflammatory Drugs
Zacks.com -
Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA
Zacks.com -
Price Over Earnings Overview: Biogen
Benzinga -
Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage
CNBC -
Biogen gets EU court ruling in favor of blocking Tecfidera generic entry
Seeking Alpha -
Why Biogen Idec (BIIB) Is Down Today
TheStreet.com 3/21/2014Biogen Idec (BIIB) dropped on Friday as the biotech sector sagged amid controversy tied to Gilead Sciences' (GILD) hepatitis C drug Sovaldi, which has been priced at $1,000 a day.
-
Biogen Idec: Earnings Up, Gauntlet Down, Headhunters All Around?
Xconomy -
Do Fundamentals Have Any Role To Play In Driving Biogen Inc.'s (NASDAQ:BIIB) Stock Up Recently?
YAHOO!Finance -
Biogen Idec Seeks Science-Savvy CEO, LifeImage Partners With EMC, GenomeQuest Aims to be Genetic Google, & More Boston-Area Life Sciences News
Xconomy
